SCHEMBL5690688

SCHEMBL5690688

O=C(Oc1ccc(N2C(=O)C3CCCCC3C2=O)cn1)N1CCC(COn2cccn2)CC1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ALDH1A1 P00352 5/20 0.37
POLB P06746 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
LIPE Q05469 4/20 0.35
MEN1 O00255 2/20 0.34
KDM4E B2RXH2 1/20 0.34
GRIN2B Q13224 1/20 0.33
GPR119 Q8TDV5 1/20 0.33
MAPK1 P28482 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
HCRTR1 O43613 1/20 0.32
HCRTR2 O43614 1/20 0.32
MGLL Q99685 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5688038 0.87 ALDH1A1 (0.38) KMT2AL3MBTL1ALDH1A1POLBSMN1; SMN2
SCHEMBL5689797 0.85 ALDH1A1 (0.36) KMT2AL3MBTL1ALDH1A1POLBSMN1; SMN2
SCHEMBL5931567 0.84 LIPE (0.34) LIPEGRIN2BGPR119
SCHEMBL5688056 0.79 LIPE (0.45) KMT2AL3MBTL1LIPEMGLL
SCHEMBL5687328 0.79 KMT2A (0.42) KMT2AL3MBTL1ALDH1A1POLBGAA
SCHEMBL5689609 0.78 KMT2A (0.47) KMT2AL3MBTL1ALDH1A1POLBSMN1; SMN2
SCHEMBL5688194 0.77 CHRM5 (0.44) KMT2AL3MBTL1ALDH1A1POLBSMN1; SMN2
SCHEMBL5688267 0.77 LIPE (0.45) KMT2AL3MBTL1ALDH1A1POLBSMN1; SMN2
SCHEMBL5687377 0.76 ALDH1A1 (0.36) KMT2AL3MBTL1ALDH1A1POLBSMN1; SMN2
SCHEMBL5687590 0.76 DGAT1 (0.44) KMT2AALDH1A1SMN1; SMN2MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160851-A1 Substituted piperidine carbamates LIPE, PNLIP, LIPC KMT2A 1520/4885L3MBTL1 2710/4885ALDH1A1 1044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.